A Contraceptive Gel Currently Under U.N. Study For Prevention Of
                  Sexually Transmitted Disease And HIV

    EATONTOWN, N.J., JULY 24 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Nasdaq: RPCX) announced today that inventory is in place
for the near-term Canadian launch of Advantage 24 (R), a vaginally
delivered contraceptive gel.
    Roberts obtained the exclusive Canadian rights to Advantage 24 from
Columbia Laboratories, Inc.  Advantage 24 broadens the women's health-
care, product line marketed by Roberts Pharmaceutical Canada which
includes Replens(R), a vaginal moisturizer, Estrace(R), for estrogen
replacement therapy, RIMSO-50(R), for interstitial cystitis, GLAXAL(R)
Base, a moisturizing cream, Prenavite(R), a prenatal vitamin supplement,
and Trandate(R) injection, which is often used to treat hypertension in
pregnant women.
    Advantage 24, which Roberts will introduce into the over-the-counter
Canadian marketplace, employs a patented Bioadhesive Delivery System to
disperse nonoxynol-9, a widely used spermicide.  Based on its favorable
safety profile, Advantage 24 is the only such product to be selected by
the United Nations Global Program on HIV/AIDS (UNAIDS) for a major
international study for the prevention of the heterosexual transmission
of sexually transmitted diseases including the human immunodeficiency
virus (HIV).
    Roberts Pharmaceutical Corporation is an international
pharmaceutical company focusing on the acquisition and development of
late-stage drugs.  Roberts currently markets its products in seven
countries and has operating subsidiaries in the U.S., Canada, and the
United Kingdom.  Roberts was recently listed in the Fortune Top 50
Fastest Growing Companies, the Inc.  Magazine Top 100 Listing of Fastest
Growing Companies, as well as by CEO Magazine's Top 50 Companies.
    This release contains forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external
factors, including assumptions relating to regulatory action and
competing products.  Any changes in such assumptions or external factors
could produce significantly different results.